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Sickle cell disease is an inherited 
disorder of hemoglobin that has a 
worldwide impact on health and 
longevity. Sickle cell disease, 
characterized by lifelong hemolytic 
anemia and a wide variety of painful 
and debilitating vaso-occlusive events, 
occurs in 70000 to 80000 Americans 
of African, Mediterranean, or Middle 
Eastern extraction¹. 
 In the United States, the life 
expectancy for patients with sickle cell 
disease is shortened by about 
30years², while in Africa, where 
comprehensive medical care is less 
available, death in early childhood is 
usual. In Nigeria the incidence is 1-2% 
of the population3. 
Medical advances in management of 
sickle cell disease has lead to 
significant increases in life expectancy 
of this group of patients. Improved 
public health, neonatal screening, 
parental and patient education, 
advances in red cell transfusion 
medicine, iron chelation therapy, 
penicillin prophylaxis for children, 
pneumococcal immunization, and 
hydroxyurea therapy have all likely 





The term sickle cell disorder refers to 
states in which the red cell undergoes 
sickling when it is deoxygenated. The 
sickle cell diseases are those 
disorders in which sickling produces 
prominent clinical manifestations. 
Included are sickle cell–hemoglobin C 
disease (hemoglobin SC disease), 
sickle cell–hemoglobin D disease 
(hemoglobin SD disease), sickle cell β-
thalassemia, and sickle cell anemia. 
The latter term is reserved for the 
homozygous state for the sickle cell 
gene5. 
There are few diseases of man whose 
etiology can be traced to as basic a 
level as sickle cell disease. Sickle cell 
anemia is due to the substitution of 
thymine for adenine in the glutamic 
acid DNA codon (GAG to GTG), which 
results, in turn, in substitution at β6 of 
valine for glutamic acid6. 
Deoxygenation of HbS leads to a 
conformational change that exposes a 
hydrophobic patch on the surface of 
the β-globin chain. Binding of this site 
to a complementary hydrophobic site 
on a β-subunit of another hemoglobin 
tetramer triggers the formation of large 
polymers7. This leads to the 
characteristic sickle or elongated 
shape of erythrocytes. Repeated or 
prolonged sickling causes progressive 
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damage to the erythrocyte membrane 
which is of primary importance in the 
pathophysiology and presentation of 
SCD. Various factors are associated 
with sickling of red cells which include 
deoxygenation, vascular stasis, low 
temperature, acidosis, infections. 
  When a cell sickles and unsickles 
repeatedly, the membrane is affected 
and the cell becomes irreversibly 
sickled; it remains so even when the 
oxygen pressure is increased. These 
are the sickled forms seen on air-dried 
films. An irreversibly sickled cell has a 
high hemoglobin concentration and a 
high calcium and low potassium 
content, and it may be ATP-
depleted8.These cells appear to be 
derived directly from reticulocytes9 but 
have a short intravascular life span, 
and the severity of the hemolytic 
process is directly related to the 
number of these cells in a patient's 
circulation10.  
 
CLINICAL FEATURES     
The newborn infant is protected by the 
high level of fetal hemoglobin in the 
red cells during the first 8 to 10 weeks 
of life. As the level declines the clinical 
manifestations of sickle cell disease 
appear, and the hematologic 
manifestations of sickle disease are 
apparent by 10 to 12 weeks of age11. 
Many patients with sickle cell anemia 
are in reasonably good health much of 
the time, achieving a steady-state level 
of fitness. This state of relative well-
being is periodically interrupted by a 
crisis that may have a sudden onset 
and occasionally a fatal outcome. The 
early recognition and subsequent 
clinical assessment of sickle crises are 
greatly facilitated by familiarity with the 
patient's steady state. 
Various types of crises occur, and 
these may be classified as follows: 
vasoocclusive (painful) crisis, aplastic 
crisis, sequestration crisis, and 
hemolytic crisis. The vasoocclusive 
crisis is the most common and is the 
hallmark of the patient with sickle cell 
disease12. The frequency with which 
such crises occur varies from almost 
daily to less than once yearly. The 
vasoocclusive crises result from 
complex interactions between 
endothelium, plasma factors, 
leukocytes, and rigid, sickled red cells 
leading to the obstruction of blood 
vessels. 
Other features of sickle cell disease 
are associated with the chronic state of 
this disease and complications arising 
thereof. These include: bony 
abnormalities like avascular necrosis 
of femoral head, hypostenuria, renal 
failure, priapism, autosplenectomy, 
jaundice, acute chest syndrome, 
stroke, retinopathy, leg ulcers, and 
infections. 
 




The demonstration in 1986 that 
prophylactic penicillin markedly 
reduces the incidence of 
pneumococcal sepsis13 provided a 
powerful incentive for the widespread 
implementation of neonatal screening 
for sickle cell disease (SCD)14. 
Neonatal screening, when linked to 
timely diagnostic testing, parental 
education, and comprehensive care, 
markedly reduces morbidity and 
mortality from SCD in infancy and 
early childhood14. It is imperative that 
all infants, including those born at 
home, be screened and that the initial 
screening test always be obtained 
prior to any blood transfusion, 
regardless of gestational or postnatal 
age. Hemoglobins (Hb) identified by 
neonatal screening are generally 
reported in order of quantity. Because 
more fetal hemoglobin (Hb F) than 
normal adult hemoglobin (Hb A) is 
present at birth, most normal infants 
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show Hb FA. Infants with 
hemoglobinopathies also show a 
predominance of Hb F at birth. Those 
with SCD show Hb S in absence of Hb 
A (FS), Hb S with another hemoglobin 
variant (e.g., FSC, FSDPunjab), or a 
quantity of Hb S greater then Hb A 
(FSA). Hundreds of other Hb variants 
may also be identified. Most of these 
variants are associated with few or no 
clinical consequences, but some are 




Sickle cell trait (SCT) is not considered 
to be a health problem, but individuals 
who test positive should be informed 
about the implications for their health 
and family planning. There are two 
major circumstances in which adults 
will learn that they have SCT: 
1. Parents of a child with SCT. When a 
newborn with SCT is identified through 
screening, at least one of the parents 
will have SCT. 
2. Pregnant women. During prenatal 
care, women from racial groups with a 
high prevalence of the sickle cell gene 
are tested for the gene.  
SCT counseling has two components 
—education and decision-making—but 
the emphasis differs in the two cases 
above. For the first group, the focus is 
on education, that is, to enable 
individuals to make informed 
decisions, in their own interest, about 
future family planning. For the second 
group, the focus is on education and 
informed decisions, in their best 




Sickle cell disease (SCD) is a complex 
condition that affects the patient, the 
family, and the patient’s and family’s 
relationship with health care providers 
and the community. It is imperative 
that teaching the skills necessary for 
coping with this illness begin at the 
time of diagnosis and continue 
throughout the life of the patient and 
that providers recognize that including 
the extended family and the 
community in the education process 
will ensure the most positive 
outcome15. Psychosocial issues 
confronting patients, families, 
providers, and the community, though 
multiple and multifactorial, can be 




Severe pain should be considered a 
medical emergency that prompts 
timely and aggressive management 
until the pain is tolerable. The following 
recommendations are for treatment in 
the emergency room, day 
treatment center, or hospital if the 
patient is admitted directly15. 
• Begin hydration. Total fluids 
should not exceed 1.5 times 
maintenance (including volume for 
drug infusions). Initial fluid should 
be 5 percent dextrose + half-
normal saline + 20 mEq KCl/L, 
adjusted for serum chemistry 
results.  
• Assess the patient for the cause of 
pain and complications. 
   Analgesics are the foundation for 
the management of sickle cell pain, 
and their use should be tailored to the 
individual patient. Sedatives and 
anxiolytics alone should not be used to 
manage pain, because they can mask 
the behavioral response to pain 
without providing analgesia. 
Management of pain associated with 
SCD consists of the use of 
nonsteroidal anti-inflammatory drugs 
(NSAIDs), opioids, and adjuvant 
medications16,17. Management of mild-
to-moderate pain should include 
NSAIDs or acetaminophen, unless 
there is a contraindication; these are 
nonsedating, so patient activities can 
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continue. If mild-to moderate pain 
persists, an opioid can be added. 
Treatment of persistent or moderate-
to-severe pain relies on repeated 
assessments and appropriate 
increases in opioid strength or dose. 
The type of oral preparation used 
depends on the characteristics and 
expected duration of the pain. If the 
patient’s pain typically is of short 
duration (less than 24 hours), opioids 
or formulations with a short duration of 
action are appropriate, with the 
advantage of quicker onset of action. 
For patients whose pain requires 
several days to resolve, a sustained 
release opioid preparation is more 
convenient to take and provides a 
more consistent analgesia15. The 
combination of nonopioid analgesics 
with opioids can permit lower doses of 
the latter. If an opioid like codeine is 
used, pain relief is accompanied by 
mild sedation that can facilitate rest. 
 
Infection  
Infection is a major complication of 
sickle cell disease (SCD). Special 
preventive measures against infection 
exist in addition to routine 
immunizations; treatment regimens are 
based on local formularies and 
antibiotic sensitivity tests. 
The single most common cause of 
death in children with SCD is 
Streptococcus pneumoniae sepsis18,19. 
The unusual susceptibility results from 
two problems: splenic malfunction, and 
failure to make specific IgG antibodies 
to polysaccharide antigens. Two 
prevention strategies are 
recommended: vaccination and 
prophylactic penicillin. The single most 
important clinical study in SCD in the 
past 20 years was a randomized, 
placebo-controlled trial that 
demonstrated that the administration 
of penicillin twice a day prevents 80 
percent of life-threatening episodes of 
childhood Streptococcus pneumoniae 
sepsis20. There are also immunization 
schedules for Haemophilus influenza, 
Neisseiria meningitides, Influenza, and 
Hepatitis B. Virtually all adults with 
sickle cell anemia are functionally 
asplenic, but their immune systems 
have matured to allow type-specific 
polysaccharide antibody production. 
Because they are not as susceptible 
as children to overwhelming sepsis 
and the incidence of sepsis is relatively 
low, there is only anecdotal evidence 
about preventive strategies. 
Streptococcus pneumoniae 
vaccination is recommended for adults 
with SCD. Some patients keep 
penicillin on hand for fever, but most 
are not prescribed penicillin 
prophylaxis routinely15. Most antibiotic 
treatments are started empirically, 
before culture results are available. 
There is need for the use of broad 
spectrum antibiotics for SCD patients 
with fever, before culture results are 
available. 
 
Transient Red Cell Aplasia 
Because the life span of red blood 
cells is greatly shortened in sickle cell 
disease (SCD), temporary suppression 
of erythropoiesis can result in severe 
anemia. Transient red cell aplasia 
(TRCA) typically is preceded by or 
associated with a febrile illness. 
Between 70 and 100 percent of 
episodes of TRCA are due to infection 
by human parvovirus B19, also the 
cause of erythema infectiosum ("fifth 
disease")21. Aplasia is the result of 
direct cytotoxicity of the parvovirus to 
erythroid precursors, although other 
progenitors may be affected in some 
conditions No experimental trials have 
been reported regarding the 
management of TRCA. Although many 
patients recover spontaneously, red 
cell transfusions should be considered 
for those who become symptomatic15. 
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Stroke and CNS Disease 
Adults presenting with acute ischemic 
stroke should be evaluated for tissue 
plasminogen activator (t-PA) 
treatment. If t-PA is not used, aspirin is 
appropriate. Adults with transient 
ischemic attack (TIA) or ischemic 
stroke should be evaluated for the 
cause of the ischemia and therapy 
should be guided by these findings. 
Alternatives include antiplatelet agents 
and warfarin. Chronic transfusion is an 
option, as used in pediatric stroke 
prevention. Several uncontrolled 
studies have documented a reduction 
in recurrent cerebral infarction using 
chronic blood transfusion with the 
target of reducing Hb S to less than 30 
percent of total hemoglobin22,23. The 
reduction in recurrent stroke risk is 
significant, but patients may still have 
a stroke despite adequate transfusion 
and low Hb S levels. The use of aspirin 
50-325mg/d for prevention of stroke is 
also recommeded15. 
Eye Disease 
Beginning in childhood, all patients 
with sickle hemoglobinopathies should 
have yearly dilated examinations by an 
ophthalmologist with expertise in 
retinal diseases. Any patient with a 
sickle hemoglobinopathy who 
experiences a change in vision should 
be referred for ophthalmologic 
consultation immediately. Central 
retinal artery occlusion, an event which 
usually results in permanent, 
devastating loss of vision, is one of the 
few bona fide ophthalmic emergencies 
which demands intervention within 
minutes to hours after the onset of 
symptoms. Treatment consists of 
hyper oxygenation combined with 
rapid reduction of eye pressure 
utilizing surgical and medical 
techniques. Vision loss from 
hemorrhage or retinal detachment also 
calls for urgent care, but, unlike acute 
vascular occlusion, can be 
appropriately addressed within 24 to 
48 hours. Any individual with a sickle 
hemoglobinopathy who sustains ocular 
or periocular trauma should be 
examined immediately by an 
ophthalmologist because of the 
increased risk of visual loss from 
elevated eye pressure associated with 
hemorrhage into the anterior chamber 
(hyphema)15. 
 
Acute Chest Syndrome (ACS) 
ACS is an acute illness characterized 
by fever and respiratory symptoms, 
accompanied by a new pulmonary 
infiltrate on a chest x ray. Because the 
appearance of radiographic changes 
may be delayed24, the diagnosis may 
not be recognized immediately. A 
major risk factor for the development 
of ACS is the hemoglobin genotype: 
the highest incidence is seen in Hb SS 
genotype (12.8 events/100 person-
years) and the lowest in Hb-S +β-
thalassemia genotype (3.9 events/100 
person years)25. ACS is the second 
most common cause of hospitalization 
in sickle cell patients and the most 
common complication of surgery and 
anesthesia26.  
Oxygen. Assessment of blood 
oxygenation requires determination of 
baseline arterial blood gases (ABG), 
and estimation of the alveolar arterial 
(A-a) oxygen gradient and the 
PaO2/FiO2 ratio. Oxygen should be 
administered to moderately hypoxemic 
patients (PaO2 = 70-80 mm Hg, O2 
saturation = 92-95 percent) nasally at 
a rate of 2 liters per min. 
Chronically hypoxemic patients in 
whom the admission PaO2 is no lower 
than in their steady state may still 
benefit from oxygen because they may 
not tolerate additional hypoxemia due 
to ACS. Control of chest pain and 
incentive spirometry can prevent 
hypoventilation in most patients27.  
Transfusions. Simple transfusions (or 
exchange transfusions) decrease the 
proportion of sickle red cells and are 
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indicated for the treatment of ACS24,28. 
Transfusions will increase the oxygen 
affinity of blood in sickle cell patients29. 
The main indication for transfusion 
therapy is poor respiratory function. 
Antibiotics. Intravenous broad-
spectrum antibiotics should be given to 
febrile or severely ill ACS patients 
since it is difficult to exclude bacterial 
pneumonia or super infection of a lung 
infarct. Other measures. Optimal pain 
control and incentive spirometry are 
important to prevent chest splinting 
and atelectasis.15 
 
Biliary Disease  
Biliary sludge is best managed by 
serial ultrasound examinations at 12- 
to 24-month intervals unless 
cholestasis occurs; at that point, 
laparoscopic cholecystectomy is 
indicted. Elective laparoscopic 
cholecystectomy has become the 
procedure of choice for symptomatic 
cholelithiasis30 because of the 
shortened hospital stay, lower cost, 
and fewer immediate surgical 
complications. One approach to 
asymptomatic or minimally 
symptomatic cholelithiasis is careful 
observation until symptoms dictate 
surgery. Bacteremia, ascending 
cholangitis, empyema, and other hyper 
acute biliary complications require 
surgery on a more urgent basis, 
consistent with good surgical 
practice15. 
 
Renal disease  
The kidney in patients with sickle cell 
disease (SCD) exhibits numerous 
structural and functional abnormalities, 
changes that are seen along the entire 
length of the nephron. These 
abnormalities include hypostenuria, 
hematuria, acute renal failure, 
glomerular abnormalities and chronic 
renal failure. Patients with SCD should 
therefore be encouraged to drink 
liberal amounts of liquids in order to 
compensate for the fluid loss that is 
brought on by hyposthenuria. 
The treatment of hematuria in SCD 
involves bed rest, maintenance of a 
high urinary flow documented by 
monitoring of intake and output, and, if 
blood loss is significant, iron 
replacement and/or blood transfusion. 
Vasopressin and epsilon-amino 
caproic acid (EACA) have both been 
used with variable success31,32. 
However, caution must be exercised 
when using EACA, as this 
antifibrinolytic agent may predispose to 
the formation of clots that can obstruct 
the urinary collecting system. If 
prolonged and life-threatening 
bleeding is coming from one kidney, 
local resection of the bleeding 
segment is preferred. Unilateral 
nephrectomy is a last resort, since 
bleeding may recur from the other 
kidney. Hematuria that occurs in SCD 
is not always a consequence of red 
cell sickling and papillary necrosis. 
Other, nonsickling causes also should 
be considered. For example, renal 
medullary carcinoma in young subjects 
with SCD and sickle cell trait (Hb AS) 
has been reported33,34. Therefore, a 
thorough evaluation is recommended 
when hematuria is initially found in 
individuals with SCD and Hb AS. 
Proteinuria, which can progress to the 
nephrotic syndrome, is the most 
common manifestation of glomerular 
injury in SCD patients. Moreover, as 
many as 40 percent of SCD-SS 
patients with nephrotic syndrome may 
goon to develop end-stage renal 
disease (ESRD)35. Therefore, patients 
with persistent proteinuria should have 
a urine collection obtained for the 
determination of 24-hour protein 
excretion, and a nephrology 
consultation should be requested for 
consideration of other, nonsickling 
causes of proteinuria and possible 
renal biopsy. ACE inhibitors ameliorate 
pathological changes such as perihilar 
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focal and segmental 
glomerulosclerosis. They also 
decrease urinary protein excretion in 
patients with early manifestations of 
sickle cell nephropathy36. 
Renal insufficiency occurs earlier in 
SCD-SS patients than it does in SCD-
SC patients37. Factors that appear to 
predict renal failure in SCD-SS 
patients include hypertension, 
proteinuria, increasingly severe 
anemia, and hematuria38. Finally, the 
risk of renal failure is increased in 
those SCD-SS patients with the 
Central African Republic (CAR) s-gene 
cluster haplotype. As there is no 
proven treatment for sickle cell 
nephropathy, every attempt should be 
made to slow its rate of progression. 
The amount of proteinuria can be 
decreased by the administration of 
ACE inhibitors, and it is conceivable 
that the progression of sickle cell 
nephropathy may be slowed by a 
prolonged course of these drugs. 
Patients should avoid nonsteroidal 
anti-inflammatory drugs (NSAIDs), 
because NSAIDs have been shown to 
produce significant declines in the 
rates of glomerular filtration and renal 
blood flow in patients with SCD37,38. 
Effective control of blood pressure has 
been reported to slow the progression 
of end stage renal disease (ESRD) in 
patients with SCD; they should be 
treated with standard approaches39. 
Because dehydration can precipitate 
vasoocclusive events, caution should 
be exercised in the use of diuretic 
agents in an individual with obligate 
hyposthenuria. Every effort must be 
made to avoid additional renal damage 
due to urinary tract infection. Infection 
must be recognized and treated 
vigorously. Follow-up should be 
maintained longer than for patients 
without SCD. 
Although erythropoietin levels are 
generally high in steady-state SCD-SS 
patients, they are not increased to the 
level that would be expected for the 
degree of anemia40. One explanation 
for the relatively decreased 
erythropoietin levels is the right-shifted 
hemoglobin-oxygen dissociation curve 
seen in SCD patients41.Erythropoietin 
levels in SCD patients fall still further 
as renal function worsens and these 
patients may require substantially 
higher doses of erythropoietin than are 
required for patients with other forms 
of ESRD42. If erythropoietin is 
ineffective, transfusions can be given; 
they must be done carefully, however, 
to avoid volume overload. As with all 
patients who develop ESRD, SCD 
patients can be treated with both 
hemodiaylsis and peritoneal dialysis, 




Beginning in early boyhood, males 
need to know that priapism is one 
aspect of SCD and that this is not an 
event that should embarrass them. 
Boys and young men, as well as their 
families, need to know that they should 
be prepared to seek medical attention 
as soon as an episode begins and that 
if untreated, priapism can result in 
impotence in the future. The males 
should know that a full bladder can 
trigger priapism, and they therefore 
need to urinate regularly. They also 
should avoid prolonged sexual activity, 
which can trigger an episode. If they 
have had more than one episode, 
medications can be prescribed that 
may prevent recurrences. The goal of 
therapy is to ease pain, make the 
erection go away, and preserve future 
erectile function. If treatment is given 
within 4 to 6 hours, the erection can 
generally be reduced with medication 
and conservative therapy15. Patients 
should be advised to drink extra fluids, 
use oral analgesics, and attempt to 
urinate as soon as priapism begins. 
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For episodes lasting more than two 
hours, patients should go to the 
emergency room to receive 
intravenous hydration and parenteral 
analgesia. According to one protocol43, 
if detumescence does not occur in 1 
hour after the patient has arrived in the 
emergency room, penile aspiration is 
initiated (procedure should be 
performed within 4 to 6 hours from 
onset of priapism). The patient 
receives conscious sedation and local 
anesthesia; blood is then aspirated 
from the corpus cavernosum with a 23-
gauge needle followed by irrigation of 
the corpora with a 1:1,000,000 solution 
of epinephrine in saline. The 
concomitant use of automated red cell 
exchange transfusions to reduce the 
sickle hemoglobin (Hb S) level to less 
than 30 percent can also be 
considered, especially if early 
intervention with irrigation fails44. If 
there is recurrence despite aspiration 
and local instillation of vaso-active 
drugs, shunting may be considered. In 
this procedure, known as the Winter 
procedure, a shunt is created between 
the glans penis and the distal corpora 
cavernosa with a Tru-cut biopsy 
needle; this allows blood from the 
distended corpora cavernosa to drain 
into the uninvolved corpus 
spongiosa45.Additional medications 
used for reversal of priapism include 
-agonists.If impotence persists for 12 
months, the patient may wish to 
consider implantation of a semi rigid 
penile prosthesis46. 
Some physicians prescribe 30 mg of 
oral pseudoephedrine at night as an 
attempt to prevent further episodes in 
those who have had priapism and 
have required aspiration and 
irrigation43.Injections of leuprolide, a 
gonadotropin releasing hormone 
analogue that suppresses the 
hypothalamic-testicular axis and the 
production of testosterone, also has 
also been used with some degree of 
success as prophylaxis against further 
episodes47. A small (11 patients) 
double-blind, placebo-controlled 
crossover study found that oral 
stilbestrol in doses of 5 mg daily for 3 
to 4 days could abort episodes of 
priapism and that much smaller doses 
could prevent recurrence48.Although 
hydroxyurea may potentially be of 
benefit49, clinical studies to determine 
its efficacy in preventing priapism have 
not been performed. 
 
Musculoskeletal Abnormalities 
Musculoskeletal manifestations of 
sickle cell disease (SCD) are common 
and may lead to severe morbidity. 
Bone and joint involvement result from 
three main causes: 1) bone marrow 
hyperplasia, which causes distortion 
and growth disturbance, particularly in 
the skull, vertebrae, and long bones; 2) 
vaso-occlusive events that lead to 
infarction of metaphyseal and 
diaphyseal bone and to osteonecrosis 
of juxta-articular bone; and 3) 
hematogenous bacterial infection that 
results in osteomyelitis and septic 
arthritis. Conservative management by 
analgesia, rehydration, transfusions 
and appropriate antibiotics are 
recommended for uncomplicated 
cases. Surgical intervention for those 
with advanced disease and for whom 
all other conservative measures have 
failed is recommended15. These 
include, core decompression and 
osteotomy for osteonecrosis, hip 
replacement, prosthesis and surgical 




Between 10 and 20 percent of patients 
with sickle cell disease (SCD) due to a 
homozygous hemoglobin S (Hb S) 
genotype (SCD-SS) develop painful, 
disfiguring, and indolent leg ulcers. 
The ulcers usually appear between 
ages 10 and 50 years and are seen 
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more frequently in males than in 
females15. Studies to prove the 
efficacy of treatment of leg ulcers are 
difficult to perform. One reason is that 
healing depends on blood circulation, 
and the cumulative time of bed rest 
and leg elevation is not easily 
monitored. In addition, the variable 
extent of wound debridement is difficult 
to quantify, and a short period of 
dependency could erase any gains 
made in the previous period.  
Ankle ulcers are painful, and the 
patient should be given moderately 
potent analgesics such as oxycodone. 
Bed rest and elevation of the leg to 
reduce edema are useful, though not 
always practical. Wet-to-dry dressings, 
even if applied only 2 or 3 times a day, 
can provide gentle debridement; 
cooperation of patients increases 
when they are permitted to dampen 
the dressing slightly before removal, 
since it is a painful process. Oral zinc 
sulfate (200 mg 3 times a day) 
probably does no harm if it does not 
cause nausea, and may be worth 
using15. The ulcer size should be 
measured at every clinic visit; seeing 
the dimensions shrink can provide 
encouragement to the patient. Some 
ulcers will not heal. Rigorous studies 
have not been done to assess the 
utility of transfusions for treating leg 
ulcers, but the ulcers seem to correlate 
with degree of anemia, which suggests 
transfusions may help. They should be 
considered for recalcitrant or recurrent 
skin ulcers if conservative therapy 
fails. If transfusions are used, they 
probably should be continued for 3 to 6 
months, and a hemoglobin 
concentration above 10 g/dL with Hb S 
levels less than 50 percent can be 
achieved15. More complete bed rest, 
systemic antibiotics, transfusions, and 
skin grafts sometimes help. If split 
thickness or pinch grafts are to be 
used, preoperative preparation of the 
ulcer bed is probably quite important. 
Quantitative bacterial cultures of 
biopsies of the bed and margin are 
advocated by some50 but not all51 
surgeons as a guide to the time for 
surgery. Intravenous arginine butyrate 
infusions have been reported to cause 
rapid healing of ankle ulcers52. 
 
Pregnancy  
Prenatal care for women with SCD 
should be managed by a 
multidisciplinary team that includes an 
obstetrician, nutritionist, primary care 
physician, and hematologist. The team 
must decide who will be responsible 
for each aspect of the patient’s care. 
Close monitoring, combined with 
prompt diagnosis and aggressive 
treatment of complications during the 
prenatal and neonatal period by a 
multidisciplinary team, will contribute to 
better outcomes15. The clinical 
problems of SCD, such as new onset 
seizures, hepatopathy, acute anemia, 
and painful episodes should be 
evaluated and managed for pregnant 
women in the same fashion as for 
women who are not pregnant. Women 
who have had previous pregnancy 
losses or who have multiple gestations 
may benefit from the early use of 
transfusions to maintain a hemoglobin 
level above 9 g/dL 15.  
 
Anaesthesia and Surgery 
• Make sure the operating and 
anesthesia teams are aware of 
the diagnosis of a sickle cell 
syndrome and the need for 
special attention.  
• In patients with SCD-SS, and 
SCD-SC, simple transfusion to 
a hemoglobin of 10 g/dLshould 
be performed before all but the  
lowest-risk procedures.  
• Patients with SCD, regardless 
of genotype, should all receive 
careful attention, with 
preoperative monitoring of 
intake and output, hematocrit, 
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peripheral perfusion, and 
oxygenation status.  
• Intraoperative monitoring of 
blood pressure, cardiac rhythm 
and rate, and oxygenation 
should be conducted for all 
surgical procedures.  
• Postoperative care should 
include attention to hydration, 
oxygen administration with 
careful monitoring, and 
respiratory therapy15.  
 
Transfusion  
Used correctly, transfusion can 
prevent organ damage and save the 
lives of sickle cell disease (SCD) 
patients. Used unwisely, transfusion 
therapy can result in serious 
complications. Once a decision is 
made to transfuse, the type of red cells 
to be given is specified and goals are 
set for the final post transfusion 
hematocrit and percent sickle 
hemoglobin (Hb S) desired.In general, 
phenotypically matched, sickle 
negative, leukodepleted packed cells 
are the blood product of choice, and a 
post transfusion hematocrit of 36 
percent or less is recommended, since 
a higher value theoretically causes 
hyper viscosity, which is dangerous to 
sickle cell patients15. Transfusions are 
used to raise the oxygen carrying 
capacity of blood and decrease the 
proportion of sickle red cells. Clinically, 
they will improve micro vascular 
perfusion of tissues. 
 
Induction of Fetal Hemoglobin 
Enhanced concentrations of 
hemoglobin F (Hb F) can inhibit sickle 
hemoglobin (Hb S) polymerization and 
red cell sickling and improve the 
clinical course of sickle cell disease 
(SCD). In a cooperative study of the 
natural history of patients with sickle 
cell anemia in the United States, the 
frequency of pain episodes correlated 
inversely with the Hb F concentration. 
Based on these epidemiologic studies 
and understanding the biophysics of 
Hb S polymerization, a search was 
launched for pharmacologic agents 
that could reverse the switch from γ- to 
β-globin chain synthesis in erythroid 
precursors. The first "hemoglobin 
switching" agent was the nucleoside 
analog 5-azacytidine53, which was 
followed by butyrate derivatives as 
compounds which increase Hb F gene 
expression. Other drugs, such as 
hydroxyurea and erythropoietin, alter 
maturation of erythroid precursors and 
promote Hb F production 
indirectly15.When both hydroxyurea 
and erythropoietin were given to 
patients with sickle cell anemia, an 
increment in Hb F concentration 
beyond that seen with hydroxyurea 
alone occurred54 
 
Hemopoietic cell transplantation  
Hematopoietic cell transplantation 
(HCT) has curative potential for a 
broad spectrum of genetic disorders, 
including sickle cell disease (SCD)55. 
The goal is to eliminate the sickle 
erythrocyte and its cellular progenitors 
and replace them with donor 
hematopoietic pluripotent stem cells 
that give rise to erythrocytes that 
express no sickle hemoglobin (Hb S), 
thereby reducing Hb S levels to those 
associated with the trait condition. The 
possibility of preventing serious 
complications from SCD, which can 
cause extensive morbidity and early 
death, is balanced by the risk of 
severe adverse events after 
transplantation15. Children with SCD 
who experience significant, 
noninfectious complications caused by 
vaso-occlusion should be considered 
for HCT, and if full siblings are 
available, HLA typing should be 
performed. 
     There are other measures which 
are still in the developmental stage 
that will be helpful in the management 
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of patients with sickle cell disease. 
These include: 
Clotrimazole-  which inhibits Gardos 
channel pathway of sickle 
hemoglobin56. 
Nitric oxide- reduces polymerization 
tendency of sickle hemoglobin57. 
Flucor ( ReothRx- poloxamer 188)  - a 
new drug under investigation that is 
said to be useful in reducing the 
duration of acute pain crises, thereby 
shortening hospital stay58. 
Gene therapy- a process whereby the 
defective gene of the sickle 




Without major breakthroughs in gene 
therapy or bone marrow 
transplantation that make these 
treatments applicable to a large 
number of patients, drug intervention 
will remain the major therapeutic 
option for sickle cell disease. The 
likelihood is low of finding a "magic 
bullet" medication that substantially 
improves sickle cell disease for all or 
even most patients. Treatment likely 
will involve the use of different agents 
alone or in combination to produce 
optimal results. Combination therapy 
currently is not an option for sickle cell 
disease, since only hydroxyurea has 
been proven to alter the course of the 
condition. Many, if not most of the 
agents currently under investigation 
likely will fall short of investigators' 
hopes. If a few survive the rigors of 
testing and joint the clinical 
armamentarium, however, we could 
mix and match drugs for patients with 
sickle cell disease. Ideally, the 
treatment regimens would include 
drugs with differing modes of action. 
Hydroxyurea, for instance, combined 
with clotrimazole would team a drug 
that enhances fetal hemoglobin 
production (hydroxyurea) with one that 
reduces erythrocyte dehydration 
(clotrimazole). For a particular patient, 
sickle cell symptoms might be 
improved substantially by neither drug 
alone. The combination, however, 
might significantly ameliorate the 
condition59. A major goal of 
investigation should be development of 
interventions that can be used in very 
young patients. Many of the problems 
experienced by adults and adolescents 
with sickle cell disease reflect 
incremental organ damage by bouts of 
hypoxia. The affected areas may 
initially be microscopic. With time, 
these foci of injury coalesce to form 
regions of macroscopic injury, such as 
avascular necrosis of the femur. 
Prevention must be the watchword as 
we seek to improve the management 
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